latest news releases from the newsroom
Lundin Mining Corporation
Lundin Mining: LUNDIN MINING 2007 THIRD QUARTER RESULTS
(all amounts are in US Dollars unless otherwise stated)
Third quarter 2007 (2006):
- Sales $292.8 million ($98.9 million)
- EBITDA (i) $142.2 million ($59.2 million)
- EBITDA, excl. one-off charge (i) (ii) $152.9 million ($59.2 million)
- Net earnings (iii) $123.1 million ($30.7 million)
- Basic earnings per share (iv) $0.32 ($0.25)
- Diluted earnings per share (iv) $0.32 ($0.25)
- Cash provided by operations $155.6 million ($59.4 million)
ACI Worldwide, Inc.
ACI Worldwide, Inc. To Release September 2007 Quarterly Financial Results
NEW YORK, Nov. 13, 2007 (PRIME NEWSWIRE) -- ACI Worldwide, Inc. (Nasdaq:ACIW) today announced that it will hold a conference call on November 29, 2007 at 4:30 pm EST to discuss the September 30, 2007 quarterly financial results. Interested persons may access a real-time audio broadcast of the teleconference at www.aciworldwide.com/investors or use the following numbers for dial in participation: US/Canada: (800) 340-8364, International/Local: (706) 634-2207. Please provide your name, the conference name ACI Worldwide, Inc. and conference code 21228227.
Infinity Pharmaceuticals, Inc.
Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Advanced Hormone-Refractory Prostate Cancer
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. 13, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. today announced that the companies have initiated a Phase 2 clinical trial of IPI-504, their lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced hormone-refractory prostate cancer (HRPC). Enrollment has commenced at San Bernardino Urological Associates Medical Group in San Bernardino, Calif., and the study is expected to expand to additional sites including the Dana-Farber Cancer Institute (DFCI), the Massachusetts General Hospital, and the Beth-Israel Deaconess Medical Center in Boston, Mass. This study marks the third solid tumor indication in which IPI-504 is being evaluated.
NewStar Financial, Inc.
NewStar Reports Third Quarter Results
BOSTON, Nov. 13, 2007 (PRIME NEWSWIRE) -- NewStar Financial, Inc. (Nasdaq:NEWS), a Boston-based specialty finance company, today reported adjusted net income for the third quarter of 2007 of $7.4 million, or $0.20 per diluted share. On a GAAP basis, the Company reported a net loss of $10.8 million, or $0.30 per diluted share, including a $16.9 million after-tax loss from the write-down of a retained residual interest in a securities portfolio sold in the second quarter, which included the vast majority of its RMBS holdings.
NewStar Financial, Inc.
NewStar Announces $125 Million Private Placement of Common Stock
BOSTON, Nov. 13, 2007 (PRIME NEWSWIRE) -- NewStar Financial, Inc. (Nasdaq:NEWS), a Boston-based specialty finance company, announced today that it has entered into a definitive agreement with certain accredited institutional investors for the private placement of 12.5 million shares of common stock at a price per share of $10.00, representing a premium of 10.4% to yesterday's closing price of $9.06. Investors in the transaction include founding shareholders, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, as well as outside investors, Swiss Re and SAB Capital. Gross proceeds of the private placement will be $125 million.
Emulex Fastest Growing HBA Provider, According to Independent Analyst Research Firm Dell'Oro Group
COSTA MESA, Calif., Nov. 13, 2007 (PRIME NEWSWIRE) -- Emulex Corporation (NYSE:ELX) today announced that new data from analyst firm Dell'Oro Group confirms it has achieved the fastest growth in the market for Fibre Channel HBAs during calendar year 2007. According to Dell'Oro Group's Q3 2007 SAN report, the Company has achieved market share gains of more than five percentage points, exceeding the growth rate of its nearest competitor. The Company's growth has been fueled by strong demand for its 4Gb/s HBAs and mezzanine cards, which gained three percentage points and eight percentage points, respectively during this period, while its nearest competitor experienced market share declines.